Let the value share Record the pace of enterprise development
2023
Multiple myeloma (MM) is a heterogeneous malignant plasma cell tumor and is one of the most common hematological malignancies. The number of new cases of MM in China in 2022 is 22,400. The first-line treatment of MM includes chemical drug combination...
2023
Protein-protein interaction (PPI) is the process of combining two or more proteins and participates in the regulation of many aspects of life processes. How to establish an efficient and accurate PPI prediction model has always been a hot and difficu...
2023
On August 1, 2023 in Chengdu, China, Chengdu Shengshi Junlian Biotechnology Co., Ltd. (hereinafter referred to as "Shengshi Junlian") announced that it has entered into an An antibody transfer agreement achieves first milestone.In February 2023, Shen...
2023
"Garbage in, Garbage out", high-quality data has always been considered the basis for AI model training. So what is "high-quality data"? How are these data obtained? Today we would like to introduce an article published in Nature Biomedical Engineeri...
2023
Recently, the 2-day China AI Drug Research and Development Conference (CAPR 2023) was held in Shanghai. The conference set up a main forum and 6 sub-forums. From the aspects of how AI affects small molecule drug design, macromolecule drug design, prot...
2023
The article "Novel application of anti-human Fc nanobody for screening high-producing CHO cells for monoclonal antibody" published by Shengshi Junlian in the journal "ENGINEERING IN LIFE SCIENCES" immediately attracted widespread attention from the i...
2020
Recently, it was learned from Chengdu Shengshi Junlian Biotechnology Co., Ltd. (referred to as "ABLINK"), located in the Tianfu Life Science Park in Chengdu Hi-tech Zone, that they have successfully screened neutralizing antibodies against SARS-CoV-2...
2020
On February 5th, the journalists came to Shengshi Junlian Biotechnology Co., Ltd. (ABLINK) located in Chengdu Tianfu Life Science Park. Five employees...
2020
Following the outbreak of COVID-19, multiple biopharmaceutical companies within Chengdu Hi-tech Zone immediately invested in the development of...
